Is sorafenib plus interferon α2b safe and effective in patents with renal cell carcinoma?

被引：4
|
作者：
Rini, Brian I. [1 ]
机构：
[1] Cleveland Clin, Dept Solid Tumor Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
NATURE CLINICAL PRACTICE UROLOGY | 2008年 / 5卷 / 03期
关键词：
combination; efficacy; interferon alpha; renal cell carcinoma; sorafenib;
D O I：
10.1038/ncpuro1036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [1] Is sorafenib plus interferon α2b safe and effective in patients with renal cell carcinoma?
    Brian I Rini
    Nature Clinical Practice Urology, 2008, 5 : 132 - 133
  • [2] Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC):: SWOG 0412.
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
  • [3] Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases
    黄涛
    China Medical Abstracts(Internal Medicine), 2013, 30 (03) : 179 - 179
  • [4] Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma
    Gollob, J. A.
    Moran, K.
    Richmond, T.
    Jones, J. M.
    Baell, T. E.
    Rathmell, W. K.
    Peterson, B. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 227
  • [5] Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?
    Ali-Reza Golshayan
    Ronald M Bukowski
    Nature Clinical Practice Urology, 2007, 4 : 586 - 587
  • [6] Is temsirolimus more safe and effective than interferon a for the treatment of advanced renal cell carcinoma?
    Golshayan, Ali-Reza
    Bukowski, Ronald M.
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (11): : 586 - 587
  • [7] Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC).
    Gollob, J.
    Richmond, T.
    Jones, J.
    Rathmell, W. K.
    Grigson, G.
    Watkins, C.
    Peterson, B.
    Wright, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
  • [8] Interferonα-2b and megestrol acetate in the treatment of advanced renal cell carcinoma -: A phase II study
    Collichio, FA
    Pandya, K
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (02): : 209 - 211
  • [9] Intralesional interferon α-2b in the treatment of basal cell carcinoma and squamous cell carcinoma:: Revisited
    Kim, KH
    Yavel, RM
    Gross, VL
    Brody, N
    DERMATOLOGIC SURGERY, 2004, 30 (01) : 116 - 120
  • [10] Is intralesional interferon α2b a safe and effective minimally invasive treatment for Peyronie's disease?
    Tiplitsky, Scott I.
    Melman, Arnold
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (01): : 22 - 23
12345